Discovering novel oncogenic targets
New Orleans American Queen
Over the last decade we have heard much about cyclin dependent kinase inhibition from numerous clinical trials in metastatic and adjuvant breast cancer on various CDK4/6 inhibitors, and to a lesser extent CDK7 and CDK9.
It’s a large family, so what about other targets within the family?
In our latest article from the annual meeting of the American Association for Cancer Research, we take a look at another such target – CDK12 – in the first of a two-part mini series…
BSB subscribers can read our latest conference coverage from AACR plus commentary and analysis – you can either log-in or click to access.
This content is restricted to subscribers
